The Anatolian Journal of Cardiology
Original Investigation

Prognostic value of interleukin-6 in atrial fibrillation: A cohort study and meta-analysis

1.

Department of Epidemiology, College of Preventive Medicine, Army Medical University (Third Military Medical University); Chongqing-People’s Republic of China

2.

Evidence-based Medicine and Clinical Epidemiology Center, Army Medical University (Third Military Medical University); Chongqing-People’s Republic of China

3.

Department of Sciences&Education, Chongqing General Hospital, University of Chinese Academy of Sciences; Chongqing-People’s Republic of China

4.

Department of Cardiology, Southwest Hospital, Army Medical University (Third Military Medical University); Chongqing-People’s Republic of China

5.

Cardiovascular Disease Center, Third Affiliated Hospital of Chongqing Medical University; Chongqing-People’s Republic of China

6.

Cardiovascular Disease Center, Third Affiliated Hospital of Chongqing Medical University; Chongqing-People’s Republic of China

7.

Department of Epidemiology, College of Preventive Medicine, Army Medical University (Third Military Medical University); Chongqing-People’s Republic of China

8.

Evidence-based Medicine and Clinical Epidemiology Center, Army Medical University (Third Military Medical University); Chongqing-People’s Republic of China

Anatol J Cardiol 2021; 25: 872-879
DOI: 10.5152/AnatolJCardiol.2021.69299
Read: 438 Downloads: 127 Published: 01 December 2021

Objective: The prognostic value of interleukin-6 (IL-6) in patients with atrial fibrillation (AF) has not been fully elucidated. Therefore, we conducted a cohort study and a meta-analysis to assess the predictive value of IL-6 for stroke and mortality in patients with AF.

Methods: A cohort study was performed in newly diagnosed non-valvular patients with AF. A total of 217 patients with AF were followed up for a mean of 27 months. A multivariate Cox regression analysis was used to evaluate the association between IL-6 and stroke/all-cause mortality. The incremental value was also assessed by adding IL-6 to the CHA2DS2-VASc score. Besides, a meta-analysis of all reported cohort studies and our cohort study was conducted to validate the association of circulating IL-6 and stroke/mortality in patients with AF.

Results: Our cohort study showed that elevated plasma level of IL-6 was an independent risk factor for predicting stroke [hazard ratio (HR)=3.81; 95% confidence interval (CI), 1.11–13.05; p=0.033] and all-cause mortality (HR=3.11; 95% CI, 1.25–7.72; p=0.015) in patients with AF. Adding IL-6 levels to CHA2DS2-VASc score showed limited improvement of the predictive power for stroke [area under curve (AUC) from 0.81 to 0.88, p=0.006]. Metaanalysis confirmed that increased circulating level of IL-6 was significantly associated with increased risk of stroke (pooled HR=1.97; 95% CI, 1.22–3.17; p=0.006) and all-cause mortality (pooled HR=2.73; 95% CI, 2.29–3.25; p<0.001).

Conclusion: Increased circulating level of IL-6 was significantly associated with greater risk of stroke and all-cause mortality in patients with AF. Adding IL-6 biomarker to the CHA2DS2-VASc score may help to determine the management of AF treatment.

Cite this article as: Jia X, Cheng X, Wu N, Xiang Y, Wu L, Xu B, et al. Prognostic value of interleukin-6 in atrial fibrillation: A cohort study and meta-analysis. Anatol J Cardiol 2021; 25: 872-9.

Files
ISSN 2149-2263 EISSN 2149-2271